Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are extremely effective at
reducing low-density lipoprotein (LDL) cholesterol and have been demonstrated to reduce …

Objectives: The purpose of this study was to characterize the determinants of plaque
progression despite achieving very low levels of low-density lipoprotein cholesterol (LDL-C) …

Large clinical trials demonstrate that control of blood pressure or hyperlipidemia reduces
risk for cardiovascular events by∼ 30%. Factors that may further reduce remaining risk are …

Background: Dyslipidemia causes coronary heart disease in middle-aged and elderly
adults, but the consequences of lipid exposure during young adulthood are unclear …

Objectives: The aim of this study was to evaluate the impact of olmesartan on progression of
coronary atherosclerosis. Background: Prior intravascular ultrasound (IVUS) trial results …

OBJECTIVE: YKL-40 is a pro-inflammatory protein highly expressed in atherosclerotic
plaques, and is related to prognosis of patients with coronary artery disease (CAD). This …

Background: The reduction in plasma LDL-C concentrations with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor (statin) therapy has been reported to reduce cardiovascular …

Согласно современным представлениям, атерогенез–это комплексный процесс,
развитие, прогрессирование и клиническая форма течения которого зависят как от …

A recent workshop sponsored by the European Commission identified atherothrombosis as
among the top current priorities for translational research in cardiovascular disease (1). In …

目的: 探讨急性冠脉综合征(ACS) 患者血清总胆红素(Tbil) 测定的临床意义以及Tbil
与冠状动脉粥样硬化严重程度之间的关系. 方法: 收集住院并行冠脉造影检查的患者232 例 …